Targeting of ibrutinib resistance driving pathways by miR-28 in ABC-DLBCL
Emigdio Álvarez-Corrales, Rocío Moreno-Palomares, Carmen Gómez‐Escolar, Mario Martínez‐Mingo, Udane Moral-Pérez, María Laguna-Herrero, Teresa Fuertes, Belén S. Estrada, Sonia M. Mur, Adriana de Bonis, Magdalena Leiva, Núria Martínez, Álvaro Somoza, Almudena R. Ramiro, Virginia G. de Yébenes
This study shows miR-28 inhibits ibrutinib resistance in ABC-DLBCL by targeting mitochondrial and mTOR pathways and improves survival in treated patients.
Leukemia · Apr 8, 2026Peer-reviewedCancer Biology